DOC — Healthpeak Properties, Inc.

The market is split rather than scared. The August 4, 2026 Q2 print (net income $0.08/sh, adjusted FFO $0.46/sh) came with a raised FY26 FFO guide, RBC reiterated Outperform and lifted its target to $24, and the July 2026 $2.1B Brookfield joint venture was well received - yet as of 2026-09-13 the shares were $20.30 with a -1.74% one-month and -1.88% three-month return and RSI at 36.0. The analyst stack is a genuine coin-flip (20 Buy, 21 Hold, 0 Sell; consensus rating 'Hold'; average target $22.38, recent-target average $23.33 versus a $19 low). The +19.55% six-month return against a slightly negative three-month return tells the same story: a strong first half of 2026 followed by a summer of digestion, with income buyers holding and growth buyers waiting for the November print.

Revenue stepped up from $556M (Q3 2023) to roughly $700M when the Physicians Realty merger closed in Q1 2024, then went flat for five quarters ($694M-$706M from Q2 2024 through Q2 2025), and has since re-accelerated: $719.4M (Q4 2025), $753.0M (Q1 2026), $771.6M (Q2 2026). Year-over-year revenue growth across those four prints runs +0.8%, +3.1%, +7.1%, +11.1% - that is a real inflection, not a blip. The profit line has not followed: operating income fell year over year in Q2 2026 ($131.5M to $124.9M), so operating margin compressed from 18.9% to 16.2% even as revenue rose 11.1%, and Q1 2026 showed the same pattern (19.2% to 15.5%). FCF swung to -$522.5M in Q2 2026 because capex jumped to $883.6M (versus $24.0M in Q1 2026) - that is development/JV funding, not decay, but it does mean the cash-flow line is volatile. GAAP EPS is noise for a REIT here (-$0.17 in Q3 2025, $0.28 in Q1 2026, $0.08 in Q2 2026), and the gross-profit line is unusable altogether (negative $627.3M in Q4 2025, negative $150.4M in Q1 2026 - a reclassification artifact); FFO of $0.46 in Q2 2026 and the raised $1.73-$1.77 guidance (~4% growth) are the real scorecard. Verdict: revenue is inflecting up, margins have not turned yet, and trailing operating cash flow is roughly flat (TTM $1,231.1M versus $1,244.6M a year earlier).

The trailing P/E of 58 and PEG of -0.133 are meaningless for a REIT - GAAP EPS is crushed by depreciation and one-off impairments. On the metrics that matter, DOC screens cheap: $20.30 divided by the $1.75 midpoint of raised 2026 FFO guidance is 11.6x, versus the 13-15x range where stabilized healthcare REITs generally trade and versus the company's own 5-year average P/S of 6.16x against a current 4.74x (the deterministic model's own label is 'Cheap vs. its own history'). Price/book is 1.785x, EV/EBITDA 12.7x (net debt of $7.65B plus a $14.0B market cap against ~$2B of EBITDA), and the dividend yield of 5.93% is roughly 150-200bp above the healthcare-REIT average. The analyst forward EPS estimate of $0.448 (45x) is another reminder not to use EPS on this name. Net: cash-flow cheap, optically expensive, and the ~70% FFO payout leaves the dividend well covered but not bulletproof.

As of 2026-09-13, $20.30 embeds about 11.6x 2026 FFO with ~70% of that paid out as dividends - the market is pricing steady-state, not growth. It is not pricing the four-quarter revenue re-acceleration (+0.8% to +11.1%) or the balance-sheet de-risking from the July 2026 Brookfield JV (long-term debt down from $10.14B at 2025-12-31 to $9.28B at 2026-06-30, cash up to $1.63B). A plain re-rate to 12.5x on the $1.75 guidance midpoint is $21.88, and 13x on a ~$1.82 2027 FFO is ~$23.70 - which is where the $22.38 consensus and $23.33 recent-average targets cluster. On the downside, 10-11x FFO is $17.50-$19.25, and in that scenario the 5.9% yield is your entire return. So the setup is mildly asymmetric to the upside, but the upside mechanism is multiple expansion, not an earnings surprise - which means it needs either falling rates or proof that lab leasing and margins are turning.

As of 2026-09-13, RSI(14) was 36.0, price was 2.9% below the 20-day SMA and 5.34% below the 50-day, but still 8.74% above the 200-day (implying an SMA200 near $18.70 and an SMA50 near $21.45). Weak short-term momentum inside an intact long-term uptrend is the classic definition of a consolidation pullback rather than a breakdown, and the +19.55% six-month return versus -1.88% over three months confirms it. RSI in the mid-30s is neither a capitulation buy nor a momentum sell. Timing implication: there is no urgency to chase; the high-$19s/low-$20s region toward the 200-day is a more sensible accumulation zone than $20.30 in the middle of the recent range, and a reclaim of the 50-day (~$21.45) would be the signal that the pullback is done.

• Interest rates and the 10-year Treasury: DOC is a levered, capital-intensive REIT ($9.28B of long-term debt at 2026-06-30, FMP debt-to-equity of 1.316), so falling yields both cut refinancing costs and expand REIT valuation multiples; the July 2026 Brookfield JV reduces reliance on the debt and equity markets.
• Long-term demographics: the expanding over-80 U.S. population is the structural demand driver for outpatient medical visits, and the secular shift of care out of hospitals into lower-cost outpatient settings favors DOC's medical office portfolio.
• Life-science funding and lab supply: biotech venture funding, lab vacancy and construction in core clusters (South San Francisco, Boston, San Diego) drive tenant credit and re-leasing spreads - the single largest swing factor in DOC's growth story.
• Private-market cap rates and the transaction bid: the $2.1B Brookfield minority-stake JV validated private-market pricing and gives DOC a recycling channel; a widening cap-rate environment would both slow that program and pressure the public multiple.
• Healthcare reimbursement and ACA/payer policy: rate changes and subsidy decisions affect health-system tenant economics, which flow through to rent-paying capacity and leasing demand.

• Q3 2026 earnings, expected early-to-mid November 2026: lab leasing retention, NOI growth, development lease-up and any further revision to FY26 FFO guidance of $1.73-$1.77 - the next real information event.
• Deployment of Brookfield JV proceeds into development or acquisitions: additional JV, monetization or buyback announcements would extend the capital-recycling narrative and support a multiple re-rate.
• Dividend cadence: the $0.10167 monthly payment ($1.22 annualized, 5.93% yield as of 2026-09-13, with the September payment payable September 25, 2026) - a raise or an accelerated buyback would signal management confidence.
• A dovish rate path: REITs are among the highest-beta sectors to falling yields, and a 5.9% yield becomes progressively more attractive as cash yields decline.
• A life-science leasing inflection - a pick-up in large-block lab deals or biotech funding would directly answer the biggest bear case on the stock.

• GAAP headline risk: Q2 2026 net income of just $63.2M ($0.08/sh) against a trailing P/E of 58, and a -$117.1M net loss booked in Q3 2025. Recurring impairments keep the headline valuation optics ugly and can spook screen-based buyers.
• Operating margin compression: margin fell to 16.2% in Q2 2026 from 18.9% a year earlier (and to 15.5% from 19.2% in Q1) despite double-digit revenue growth - if property operating costs and D&A keep outrunning rent growth, FFO growth stalls.
• Cash-flow volatility: free cash flow was -$522.5M in Q2 2026 on $883.6M of capex. That is investment rather than deterioration, but it means the dividend and development program depend on capital recycling (the Brookfield JV) rather than internally generated cash.
• Life-science tenant credit and lab oversupply: pockets of tenant distress or renewed vacancy in core clusters would hit occupancy, re-leasing spreads and the credibility of the ~4% FFO growth story.
• Leverage and rate sensitivity: $9.28B of long-term debt and a 1.316 debt-to-equity ratio at 2026-06-30 leave DOC exposed to refinancing costs and cap-rate expansion; a 100bp move in cap rates is worth several turns of equity value.
• Dividend coverage: roughly 70% of FFO and likely 75%+ of AFFO - comfortable, but with limited cushion if FFO growth reverses.

DOC is an income holding, not a compounder, and it is priced as one: 11.6x the midpoint of raised 2026 FFO guidance, a 5.93% dividend yield covered ~70% by FFO, a balance sheet materially de-risked by the July 2026 $2.1B Brookfield JV (long-term debt down to $9.28B from $10.14B six months earlier), and revenue growth that has accelerated for four straight quarters to +11.1% year over year. The offset is that the profit line has not followed - operating margin compressed from 18.9% to 16.2% year over year and Q2 free cash flow was -$522.5M on heavy development spend - so you are buying an improving top line, not yet an improving bottom line. At $20.30 as of 2026-09-13 you are paid ~5.9% to wait for a re-rate toward $22; that is a reasonable but not compelling risk/reward, and I would want either the mid-to-high $19s or hard evidence of margin stabilization before calling it a buy.

I used a P/FFO relative valuation, the standard lens for a REIT: management's raised 2026 FFO guidance midpoint of $1.75 times a justified 12.5x multiple (below the 13-15x healthcare-REIT average to reflect DOC's life-science tenant-credit exposure, above the current ~11.6x to reflect the Brookfield-de-risked balance sheet and accelerating revenue) gives $21.88, cross-checked against a required-yield calculation ($1.22 annualized dividend divided by 5.6% equals $21.79) and a 2027E FFO of roughly $1.82 at 12.25x ($22.30); blending those three inputs lands at $22.00 as of 2026-09-13.